Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT

Autor: José M. Marín, Luis Mateos, Juan Roldán, José M. Echave-Sustaeta, Sergi Pascual-Guardia, Maria V. Pardo, Beatriz Velasco, C. Elaine Jones, Sally Kilbride, David A. Lipson

Publikováno v: Therapeutic Advances in Respiratory Disease, Vol 14 (2020)

Objectives: The IMPACT trial has compared the benefit in the reduction of moderate/severe exacerbations of single inhaler triple therapy (SITT) with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus dual therapy with FF/VI (ICS/LABA

Externí odkaz: https://doaj.org/article/4e4da6406d1c4f648f051a3e419dd5af

Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT

Autor: José M Echave-Sustaeta, C. Elaine Jones, Beatriz Velasco, Sergi Pascual-Guardia, Sally Kilbride, José M Marín, Juan Roldán, Luis Mateos, David A. Lipson, Maria V Pardo

Publikováno v: Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Zaguán: Repositorio Digital de la Universidad de Zaragoza
Universidad de Zaragoza
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Therapeutic Advances in Respiratory Disease

Objectives: The IMPACT trial has compared the benefit in the reduction of moderate/severe exacerbations of single inhaler triple therapy (SITT) with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus dual therapy with FF/VI (ICS/LABA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0e5151aeb8f492efaa30b527fc5c22d
http://hdl.handle.net/10230/52530